While many sectors rise and fall with liquidity cycles, life sciences operate under a different logic.

People do not stop aging.
Diseases do not pause during recessions.
Healthcare demand does not wait for market sentiment.

This is why medicine and biotechnology have always been — and will remain — a structural allocation, not a cyclical trade.

At #ARCB, we view 2026 as a turning point where capital efficiency becomes as important as scientific innovation.

For over a decade, biotech innovation was often driven by:

• Large funding rounds

• Long burn cycles

• Binary outcomes

• Capital replacing discipline

That model is breaking.

In a higher-rate, selective-capital environment:

Money is no longer the innovation — efficiency is.

Investors now demand:

• Clear milestone progression

• Faster validation cycles

• Capital-light experimentation

• Defined paths to commercialization

Biotech that cannot demonstrate capital discipline will struggle — regardless of scientific promise.

Capital will increasingly favor innovation that:

• Shortens development timelines

• Reduces trial cost and complexity

• Leverages data and AI

• Integrates platform-based R&D

Key growth areas include:

• AI-assisted drug discovery

• Precision and personalized medicine

• Diagnostics and early detection

• Digital therapeutics

• Platform biotech models

The shift is clear:

From breakthrough-at-any-cost to scalable innovation.

In 2026, investors will ask:

• How much progress per dollar?

• Can this platform reuse research outputs?

• Does technology compound learning?

• Is risk diversified across pipelines?

Capital will flow toward teams that:

• Build reusable platforms

• Combine biology with computation

• Reduce dependency on single assets

Efficiency is no longer a financial metric.
It is a scientific strategy.

AI changes the economics of life sciences by:

• Reducing trial-and-error

• Improving target identification

• Predicting failure earlier

• Optimizing clinical trial design

This shifts biotech from:

Capital-intensive guessing
to
Data-driven probability management

By 2026, biotech without #AI integration will be structurally disadvantaged.

Despite volatility, institutions remain committed because:

• Healthcare demand is non-discretionary

• Outcomes are decoupled from consumer sentiment

• Innovation creates long-term value

• Regulatory frameworks, while strict, provide defensibility

In a world of uncertainty, medicine offers:

Defensive growth with asymmetric upside.

By 2026, expect capital to:

• Move from single-asset bets to platforms

• Favor early proof-of-concept over late-stage burn

• Blend VC, strategic, and institutional capital

• Seek clearer commercialization paths

Capital becomes:

More patient, but less forgiving.

At #ARCB, we see medicine and biotech as:

• A core structural pillar

• A convergence of science, data, and capital discipline

• A sector where real innovation cannot be faked

Our focus is on:

• Platform-driven biotech

• AI-enabled life sciences

• Capital-efficient innovation models

• Clear translation from research to impact

We are not funding science for headlines.
We are backing innovation that can scale, survive, and deliver.

Medicine and biotech are not optional allocations.

They are inevitable.

By 2026, the winners will not be:

• The loudest breakthroughs

• The largest funding rounds

They will be:

• The most efficient innovators

• The fastest learners

• The best translators of science into outcomes

Capital will follow not just discovery —
but disciplined innovation.

#ARCB

While many sectors rise and fall with liquidity cycles, life sciences operate under a different logic.

People do not stop aging.
Diseases do not pause during recessions.
Healthcare demand does not wait for market sentiment.

This is why medicine and biotechnology have always been — and will remain — a structural allocation, not a cyclical trade.

At #ARCB, we view 2026 as a turning point where capital efficiency becomes as important as scientific innovation.

For over a decade, biotech innovation was often driven by:

• Large funding rounds

• Long burn cycles

• Binary outcomes

• Capital replacing discipline

That model is breaking.

In a higher-rate, selective-capital environment:

Money is no longer the innovation — efficiency is.

Investors now demand:

• Clear milestone progression

• Faster validation cycles

• Capital-light experimentation

• Defined paths to commercialization

Biotech that cannot demonstrate capital discipline will struggle — regardless of scientific promise.

Capital will increasingly favor innovation that:

• Shortens development timelines

• Reduces trial cost and complexity

• Leverages data and AI

• Integrates platform-based R&D

Key growth areas include:

• AI-assisted drug discovery

• Precision and personalized medicine

• Diagnostics and early detection

• Digital therapeutics

• Platform biotech models

The shift is clear:

From breakthrough-at-any-cost to scalable innovation.

In 2026, investors will ask:

• How much progress per dollar?

• Can this platform reuse research outputs?

• Does technology compound learning?

• Is risk diversified across pipelines?

Capital will flow toward teams that:

• Build reusable platforms

• Combine biology with computation

• Reduce dependency on single assets

Efficiency is no longer a financial metric.
It is a scientific strategy.

AI changes the economics of life sciences by:

• Reducing trial-and-error

• Improving target identification

• Predicting failure earlier

• Optimizing clinical trial design

This shifts biotech from:

Capital-intensive guessing
to
Data-driven probability management

By 2026, biotech without #AI integration will be structurally disadvantaged.

Despite volatility, institutions remain committed because:

• Healthcare demand is non-discretionary

• Outcomes are decoupled from consumer sentiment

• Innovation creates long-term value

• Regulatory frameworks, while strict, provide defensibility

In a world of uncertainty, medicine offers:

Defensive growth with asymmetric upside.

By 2026, expect capital to:

• Move from single-asset bets to platforms

• Favor early proof-of-concept over late-stage burn

• Blend VC, strategic, and institutional capital

• Seek clearer commercialization paths

Capital becomes:

More patient, but less forgiving.

At #ARCB, we see medicine and biotech as:

• A core structural pillar

• A convergence of science, data, and capital discipline

• A sector where real innovation cannot be faked

Our focus is on:

• Platform-driven biotech

• AI-enabled life sciences

• Capital-efficient innovation models

• Clear translation from research to impact

We are not funding science for headlines.
We are backing innovation that can scale, survive, and deliver.

Medicine and biotech are not optional allocations.

They are inevitable.

By 2026, the winners will not be:

• The loudest breakthroughs

• The largest funding rounds

They will be:

• The most efficient innovators

• The fastest learners

• The best translators of science into outcomes

Capital will follow not just discovery —
but disciplined innovation.

#ARCB